Charles River Laboratories International, Inc. (CRL)
Similar size · 1.06x market cap
Diagnostics & Research
YouTube · Q2 2026 · 2026-08-08
ICLR · NasdaqGS
ICON Public Limited Company
Diagnostics & Research · Ireland
USD 164.11-3.3% daily changeQuote 2026-09-18 · USD
- Market cap (USD)
- US$12.66B
- Trailing P/E
- 248.65x
- Forward P/E
- 13.91x
- Quarterly revenue growth
- 1.2%
- Trailing net margin
- 0.3%
- Indicated dividend yield
- —
Snapshot 2026-09-20 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Next earnings: 2026-10-21 (provider estimate, not issuer-confirmed).
Company background
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Company websiteQ2 2026
Go beyond the headline.
ICON plc (ICLR): Best Bookings in CRO History — and the Stock Fell 8% — Is ICLR Stock a Buy?
Published 2026-08-01
Comparable businesses
ICLR peer comparison
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
| Metric | ICLRICON Public Limited CompanySnapshot 2026-09-20Financial period: 2026-06-30 | CRLCharles River Laboratories International, Inc.Snapshot 2026-09-20Financial period: 2026-06-27 | RVTYRevvity, Inc.Snapshot 2026-09-20Financial period: 2026-07-05 | Peer medianSimilar-size peers only |
|---|---|---|---|---|
| Market capMarket value, converted to USD | US$12.66B | US$13.39B | US$16.01B | US$14.70Bn=2 |
| Forward P/EProvider forward earnings estimate | 13.91x | 21.92x | 24.34x | 23.13xn=2 |
| EV / EBITDAEnterprise value / trailing EBITDA | 29.15x | 19.04x | 20.92x | 19.98xn=2 |
| Revenue growthLatest quarter vs prior-year quarter | 1.2% | -2.7% | 1.3% | -0.7%n=2 |
| Operating marginLatest reported quarter | 9.4% | 15.1% | 17.1% | 16.1%n=2 |
| Free cash flow yieldTrailing cash flow / market cap | 4.9% | 3.5% | 3.8% | 3.6%n=2 |
| Net debt / EBITDANet debt / trailing EBITDA | 4.96x | 3.35x | 2.65x | 3.00xn=2 |
| Debt / equityTotal debt / positive book equity | 0.38x | 1.05x | 0.46x | 0.76xn=2 |
| Trailing P/ETrailing twelve-month earnings | 248.65x | — | 68.97x | — |
| Price / bookPrice / positive book equity per share | 1.35x | 4.67x | 2.21x | 3.44xn=2 |
| EV / salesEnterprise value / trailing revenue | 1.84x | 4.04x | 6.29x | 5.17xn=2 |
| Earnings growthLatest quarter vs prior-year quarter | -63.3% | — | 1.2% | — |
| Gross marginTrailing twelve months | 23.9% | 34.6% | 55.0% | 44.8%n=2 |
| Net marginTrailing twelve months | 0.3% | -6.0% | 8.2% | 1.1%n=2 |
| Return on equityProvider trailing return; positive equity only | 0.3% | -7.5% | 3.2% | -2.2%n=2 |
| Free cash flow marginTrailing free cash flow / revenue | 7.5% | 11.7% | 20.8% | 16.3%n=2 |
| Dividend yieldIndicated annual dividend / price | — | — | 0.2% | — |
| Earnings payoutProvider trailing dividend payout | 0.0% | 0.0% | 13.5% | 6.7%n=2 |
| Current ratioCurrent assets / current liabilities | 0.95x | 1.35x | 1.80x | 1.57xn=2 |
| BetaProvider historical market sensitivity | 1.20 | 1.41 | 1.09 | 1.25n=2 |
YouTube · Q2 2026 · 2026-08-08
YouTube · Q2 2026 · 2026-08-10
Comparison methodology & limitations
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Financial trends
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Revenue
Reported figures
Financial data & calculation notes
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Valuation & price history
Adjusted closing price
Price history loads separately.
Price figures
Earnings-multiple scenario
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-09-20. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Research history for ICLR
Q2 20262026-08-01
ICON plc (ICLR): Best Bookings in CRO History — and the Stock Fell 8% — Is ICLR Stock a Buy?
Presentation · 2026-08-01 · YouTube
Q1 20262026-05-28
ICLR Stock: BUY Call - Accounting Cloud Lifts +17% Q1 2026
Presentation · 2026-05-28 · YouTube